Credit Suisse on Prometheus (RXDX): 'Roivant’s Ph2b UC Results Support Anti-TL1A Approach; Prometheus’ PRA023 Maintains Best-in-Class Profile'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/22/2026

1. WMT
2. ROST
3. AAP
4. NVDA
5. SPY
6. AVGO
7. SPCX
8. BJ
9. BABA
10. OSIS

Go back to Credit Suisse on Prometheus (RXDX): 'Roivant’s Ph2b UC Results Support Anti-TL1A Approach; Prometheus’ PRA023 Maintains Best-in-Class Profile'

RBC Capital on Prometheus Biosciences Inc (RXDX): 'continue to see PRA023 with best-in-class potential in UC'

January 4, 2023 11:33 AM EST

RBC Capital analyst Gregory Renza reiterated an Outperform rating and $111.00 price target on Prometheus Biosciences Inc (NASDAQ: RXDX).

The analyst comments "This morning, ROIV disclosed positive topline of their recently licensed TL1A antibody RVT-3101 from PFE (link) from the induction phase of the ph.IIb trial... More

Truist Securities on Roivant Sciences (ROIV): 'RVT-3101 looks competitive in UC with differentiated safety/efficacy profile'

January 4, 2023 9:35 AM EST

Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $19.00 price target on Roivant Sciences (NASDAQ: ROIV)

The analyst comments "This morning, ROIV reported interim data from the induction period from its controlled Ph2b study evaluating RVT-3101, TL1A that it recently in-licensed... More